(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are BARBARA BUI, ASETEK, and FAURECIA.

The three biggest losers today are BERGENBIO, ATENOR, and ORPEA.

Winners today

1. BARBARA BUI (BUI.PA)

31.25% Price Change

Barbara Bui SA engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in France and internationally. The company offers jackets, tops and shirts, T-shirts, pants, dresses and skirts, coats, leather products, mesh, and tailored cloths; shoes; bags; and accessories, such as scarves, belts, card holder and key ring, wallets, and jewelries. It offers its products through wholesale distributors, as well as online and offline stores. The company was founded in 1983 and is based in Paris, France.

CAC 40 ended the session with BARBARA BUI rising 31.25% to €10.50 on Monday while CAC 40 fell 0.18% to €7,478.16.

Earnings Per Share

As for profitability, BARBARA BUI has a trailing twelve months EPS of €2.01.

PE Ratio

BARBARA BUI has a trailing twelve months price to earnings ratio of 5.22. Meaning, the purchaser of the share is investing €5.22 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.49%.

More news about BARBARA BUI.

2. ASETEK (ASTK.OL)

27.41% Price Change

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Oslo Børs Benchmark Index_GI ended the session with ASETEK rising 27.41% to €4.23 on Monday, after five successive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.39% to €1,220.66, following the last session’s upward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.73.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ASETEK’s stock is considered to be overbought (>=80).

More news about ASETEK.

3. FAURECIA (EO.PA)

13.37% Price Change

Faurecia S.E., together with its subsidiaries, manufactures and sells automotive technology solutions in France, Germany, other European countries, the Americas, Asia, and internationally. It operates through Seating, Interiors, Clean Mobility, Electronics, Lighting, and Lifecycle Solutions segments. The Seating segment designs and manufactures vehicle seats, seating frames, covers, and comfort solutions, as well as adjustment mechanisms. The Interior segment designs, manufactures, and assembles instrument panels, cockpits, and door panels and modules, as well as center consoles, and sustainable materials. The Clean Mobility segment designs and manufactures exhaust system solutions for passenger and commercial vehicles; fuel cell electric vehicles; and aftertreatment solutions for commercial vehicles, as well as zero-emissions solutions. The Electronics segment designs and manufactures display technologies, driver assistance systems, and cockpit electronics, as well as sensors and actuators, lighting/body electronics, energy management, and HMI/displays. The Lighting segment designs and manufactures lighting technologies. The Lifecycle Solutions segment provides solutions extending the vehicle lifecycle, as well as workshop equipment and special original equipment. The company was incorporated in 1929 and is headquartered in Nanterre, France.

CAC 40 ended the session with FAURECIA jumping 13.37% to €20.94 on Monday, following the last session’s downward trend. CAC 40 dropped 0.18% to €7,478.16, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, FAURECIA has a trailing twelve months EPS of €-2.52.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FAURECIA’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for FAURECIA is 232366 which is 83.81% below its average volume of 1435470.

Volatility

FAURECIA’s last week, last month’s, and last quarter’s current intraday variation average was 2.76%, 0.36%, and 3.12%.

FAURECIA’s highest amplitude of average volatility was 3.07% (last week), 2.29% (last month), and 3.12% (last quarter).

More news about FAURECIA.

4. OREGE (OREGE.PA)

11.76% Price Change

Orege Société Anonyme designs, develops, operates, manufactures, and markets municipal and industrial sludge, and effluents treatment solutions in France, the United States, Japan, Germany, and the United Kingdom. The company offers SLG solution for conditioning, treating, and recovering municipal and industrial sludge; SLG-F, a combination of SLG conditioning solution; and Flosep for sludge separation and thickening tool. It also provides after-sales, installation and commissioning, operator training, warranty extensions, maintenance, and process line optimization services. The company was incorporated in 2005 and is headquartered in Voisins-Le-Bretonneux, France. Orege Société Anonyme is a subsidiary of Eren Groupe SA.

CAC 40 ended the session with OREGE jumping 11.76% to €0.29 on Monday while CAC 40 dropped 0.18% to €7,478.16.

Earnings Per Share

As for profitability, OREGE has a trailing twelve months EPS of €-0.1.

Revenue Growth

Year-on-year quarterly revenue growth grew by 36.5%, now sitting on 2.55M for the twelve trailing months.

Moving Average

OREGE’s value is way below its 50-day moving average of €0.33 and way under its 200-day moving average of €0.51.

More news about OREGE.

5. NANOBIOTIX (NANO.PA)

9.24% Price Change

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

CAC 40 ended the session with NANOBIOTIX rising 9.24% to €4.91 on Monday, after three successive sessions in a row of losses. CAC 40 dropped 0.18% to €7,478.16, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.62.

Moving Average

NANOBIOTIX’s value is way above its 50-day moving average of €3.45 and way higher than its 200-day moving average of €3.72.

More news about NANOBIOTIX.

6. PIERRE VAC BSA ACT (VACBS.PA)

8.7% Price Change

CAC 40 ended the session with PIERRE VAC BSA ACT rising 8.7% to €0.25 on Monday, after successive sessions in a row of losses. CAC 40 slid 0.18% to €7,478.16, after two sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Yearly Top and Bottom Value

PIERRE VAC BSA ACT’s stock is valued at €0.25 at 22:40 EST, under its 52-week high of €0.26 and way above its 52-week low of €0.22.

More news about PIERRE VAC BSA ACT.

7. HOFSETH BIOCARE (HBC.OL)

8.65% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE rising 8.65% to €3.39 on Monday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0.39% to €1,220.66, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.38.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HOFSETH BIOCARE’s stock is considered to be overbought (>=80).

More news about HOFSETH BIOCARE.

8. ENSURGE MICROPOWER (ENSU.OL)

8.53% Price Change

Ensurge Micropower ASA designs, develops, and produces ultrathin energy storage solutions for wearable devices, connected sensors, and other applications. Its solid-state lithium battery technology enables it to produce rechargeable batteries with high energy densities. The company was formerly known as Thin Film Electronics ASA and changed its name to Ensurge Micropower ASA in June 2021. Ensurge Micropower ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ENSURGE MICROPOWER jumping 8.53% to €0.14 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.39% to €1,220.66, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, ENSURGE MICROPOWER has a trailing twelve months EPS of kr-1.15.

Volatility

ENSURGE MICROPOWER’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.16%, a negative 4.17%, and a positive 6.29%.

ENSURGE MICROPOWER’s highest amplitude of average volatility was 2.38% (last week), 7.14% (last month), and 6.29% (last quarter).

More news about ENSURGE MICROPOWER.

9. ARRIBATEC GROUP (ARR.OL)

7.92% Price Change

Arribatec Group ASA, a software and consulting company, provides digital business solutions in Norway, Europe, the Americas, and internationally. The company offers solutions for businesses, including ERP systems, integrations, consulting, health checks, develops, HR and payroll, financial and project planning, bank solutions, and travel and expenses. Its solutions include QualiWare, a management system that structures and visualizes processes, activities, regulations, and requirements; Unit4 solutions; RamBase, an ERP business solution that gives control over the value chain; Power BI solutions; Hypergene, a business management tool; Adra Suite that integrates with other financial systems; Microsoft 365; CatalystOne; and Pagero that ensures compliance with legal and electronic billing requirements. The company was incorporated in 1998 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ARRIBATEC GROUP jumping 7.92% to €5.20 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.39% to €1,220.66, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ARRIBATEC GROUP has a trailing twelve months EPS of kr-1.57.

Volume

Today’s last reported volume for ARRIBATEC GROUP is 500444 which is 262.52% above its average volume of 138043.

Volatility

ARRIBATEC GROUP’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.44%, a positive 2.37%, and a positive 3.45%.

ARRIBATEC GROUP’s highest amplitude of average volatility was 4.09% (last week), 3.77% (last month), and 3.45% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ARRIBATEC GROUP’s stock is considered to be oversold (<=20).

More news about ARRIBATEC GROUP.

10. MITHRA (MITRA.BR)

7.2% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA rising 7.2% to €2.61 on Monday while BEL 20 slid 0.01% to €3,736.57.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-1.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -176.58%.

More news about MITHRA.

Losers Today

1. BERGENBIO (BGBIO.OL)

-49.13% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO sliding 49.13% to €0.99 on Monday while Oslo Børs Benchmark Index_GI fell 0.39% to €1,220.66.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.5.

Volume

Today’s last reported volume for BERGENBIO is 2838110 which is 880.73% above its average volume of 289387.

Volatility

BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 6.66%, a negative 1.03%, and a positive 3.55%.

BERGENBIO’s highest amplitude of average volatility was 6.66% (last week), 5.29% (last month), and 3.55% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be oversold (<=20).

More news about BERGENBIO.

2. ATENOR (ATEB.BR)

-21.34% Price Change

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

BEL 20 ended the session with ATENOR dropping 21.34% to €30.60 on Monday, following the last session’s upward trend. BEL 20 slid 0.01% to €3,736.57, after two successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-0.13.

Volume

Today’s last reported volume for ATENOR is 4656 which is 85.57% above its average volume of 2509.

More news about ATENOR.

3. ORPEA (ORP.PA)

-13.28% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA dropping 13.28% to €2.18 on Monday while CAC 40 slid 0.18% to €7,478.16.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-4.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.36%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 4.52B for the twelve trailing months.

Volatility

ORPEA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.40%, a negative 1.81%, and a positive 4.31%.

ORPEA’s highest amplitude of average volatility was 1.88% (last week), 4.04% (last month), and 4.31% (last quarter).

Moving Average

ORPEA’s value is way below its 50-day moving average of €2.48 and way below its 200-day moving average of €8.12.

Yearly Top and Bottom Value

ORPEA’s stock is valued at €2.18 at 22:40 EST, way below its 52-week high of €27.28 and way higher than its 52-week low of €1.74.

More news about ORPEA.

4. FINATIS (FNTS.PA)

-8.91% Price Change

Finatis Société Anonyme operates in the food distribution business in France and Latin America. It operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. The company also distributes sports equipment under the Go Sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. The company was incorporated in 1971 and is headquartered in Paris, France. Finatis Société Anonyme is a subsidiary of Euris SAS.

CAC 40 ended the session with FINATIS falling 8.91% to €4.60 on Monday while CAC 40 fell 0.18% to €7,478.16.

Earnings Per Share

As for profitability, FINATIS has a trailing twelve months EPS of €-23.79.

Volume

Today’s last reported volume for FINATIS is 20 which is 91.11% below its average volume of 225.

More news about FINATIS.

5. FUT.CLUBE PORTO (FCP.LS)

-8.85% Price Change

Futebol Clube do Porto – Futebol, S.A.D., together with its subsidiaries, participates in professional football competitions, and the sporting events promotion and organization in Portugal. It also engages in the image rights commercialization, sponsoring, merchandising, and products licensing activities; production, editing, and commercialization of multimedia material, as well as Internet, periodical, and non-periodical publications; and sport equipment management and exploration business, as well as insurance broking activities. In addition, the company organizes and sells travel and tour packages; and tickets and seat reservations, as well as represents travel agencies and tourism. Further, it is involved in the concept, design, development, production, direction, promotion, marketing, acquisition, exploration rights, recording, distribution, and dissemination of works and audiovisual programs, multimedia, television, video, cinema, theme, Internet, channels, tourist events, and cultural and sporting in any formats and systems. Additionally, the company manages, operates, and provides services in the areas of recording, production, and communication of audiovisual works, television shows, sounds, images, and other audiovisuals; and edits periodic publicities, books, and multimedia. It also explores for the Porto Canal cable television channel; and produces and executes advertisings, news reports, documentaries, and TV programs in video support. The company was founded in 1893 and is headquartered in Porto, Portugal.

PSI ended the session with FUT.CLUBE PORTO falling 8.85% to €1.03 on Monday, after three consecutive sessions in a row of losses. PSI slid 0.8% to €5,994.82, after three sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, FUT.CLUBE PORTO has a trailing twelve months EPS of €0.97.

PE Ratio

FUT.CLUBE PORTO has a trailing twelve months price to earnings ratio of 1.06. Meaning, the purchaser of the share is investing €1.06 for every euro of annual earnings.

More news about FUT.CLUBE PORTO.

6. FOUNTAIN (FOU.BR)

-8.49% Price Change

Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in Europe. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was founded in 1972 and is based in Braine-l'Alleud, Belgium.

BEL 20 ended the session with FOUNTAIN dropping 8.49% to €0.97 on Monday, after two successive sessions in a row of losses. BEL 20 fell 0.01% to €3,736.57, after two sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, FOUNTAIN has a trailing twelve months EPS of €-0.16.

Volume

Today’s last reported volume for FOUNTAIN is 100 which is 40.11% below its average volume of 167.

Volatility

FOUNTAIN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.18%, a negative 4.31%, and a positive 8.39%.

FOUNTAIN’s highest amplitude of average volatility was 18.44% (last week), 11.23% (last month), and 8.39% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FOUNTAIN’s stock is considered to be overbought (>=80).

More news about FOUNTAIN.

7. CARASENT (CARA.OL)

-7.76% Price Change

Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as care givers; and Ad Curis, a journal and professional system that delivers forward-thinking services to rehabilitation, substance abuse treatment, and mental health care, as well as organizations within upbringing and preventive works. It also provides Metodika EPM, a solution for medium sized private clinics and hospitals; Medrave M4, a program that offers healthcare professionals with an overview of the patient treatment group; Confrere, a video solution for physicians; and Plustoo, a software solution that collects, analyses, and visualizes data, as well as enables occupational health providers, employers, and employees to collaborate for healthy and sustainable work environment. In addition, the company provides Ad Voca; and Ad Opus, a system that structures work processes to follow-up participants in a course of measures for companies that work with inclusion into working life. Carasent ASA was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with CARASENT dropping 7.76% to €14.74 on Monday while Oslo Børs Benchmark Index_GI dropped 0.39% to €1,220.66.

Earnings Per Share

As for profitability, CARASENT has a trailing twelve months EPS of kr0.07.

PE Ratio

CARASENT has a trailing twelve months price to earnings ratio of 210.57. Meaning, the purchaser of the share is investing kr210.57 for every norwegian krone of annual earnings.

Volatility

CARASENT’s last week, last month’s, and last quarter’s current intraday variation average was 7.69%, 0.15%, and 2.47%.

CARASENT’s highest amplitude of average volatility was 8.12% (last week), 3.80% (last month), and 2.47% (last quarter).

More news about CARASENT.

8. EXMAR (EXM.BR)

-7.6% Price Change

Exmar NV provides shipping and energy supply chain solutions worldwide. It operates through three segments: Shipping, Infrastructure, and Supporting Services. The company transports liquefied gas products, such as liquid petroleum gas, butane, propane, anhydrous ammonia, and petrochemical gases. It also engages in ownership and leasing of offshore assets; asset construction; and provision of engineering services related to marine vessels, ships, and offshore units to the marine oil and gas industry. In addition, the company builds, owns, and operates LNG infrastructure comprising floating liquefaction of gas fields, and floating storage and regasification units, as well as provides ship-to-ship transfer services. Further, it provides ship management services, consultancy and engineering, and travel agency services; and manufactures ropes for marine and offshore applications. Additionally, the company designs, builds, installs, and operates floating production, storage, and offloading units; and operates, installs, and maintains contractor, mining companies, drilling contractors, and accommodation barges. Exmar NV was founded in 1829 and is headquartered in Antwerp, Belgium.

BEL 20 ended the session with EXMAR falling 7.6% to €10.94 on Monday, following the last session’s downward trend. BEL 20 fell 0.01% to €3,736.57, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, EXMAR has a trailing twelve months EPS of €5.07.

PE Ratio

EXMAR has a trailing twelve months price to earnings ratio of 2.16. Meaning, the purchaser of the share is investing €2.16 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EXMAR’s stock is considered to be overbought (>=80).

More news about EXMAR.

9. SANOFI NV23 (SANNV.PA)

-6.96% Price Change

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

CAC 40 ended the session with SANOFI NV23 falling 6.96% to €97.60 on Monday, after successive sessions in a row of losses. CAC 40 slid 0.18% to €7,478.16, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 46.2B for the twelve trailing months.

Moving Average

SANOFI NV23’s value is above its 50-day moving average of €92.82 and above its 200-day moving average of €91.42.

More news about SANOFI NV23.

10. IMERYS (NK.PA)

-6.67% Price Change

Imerys S.A. provides mineral-based specialty solutions for various industries worldwide. The company operates through Performance Minerals and High Temperature Materials and Solutions segments. It provides additives for interior decorative paints, as well as marine protection, facade coating, can coating; and adhesives and sealants. In addition, the company offers minerals for technical ceramics and traditional ceramics comprising floor and wall tiles, large slabs, sanitaryware, and tableware; and components for the production of high purity silicon metal for used to manufacture aluminum alloys, electronics, and solar panels, as well as for construction industry, such as insulation ceiling tiles. Further, it provides functional additives for plastics and thermoset for use in construction and infrastructure industries; fillers and coatings for board and packaging applications; filtration agents for liquids and blood plasma; and graphite and carbon-based solutions for lithium-ion and alkaline batteries, polymers, fuel cells, carbon brushes, and others. Additionally, the company offers refractory minerals and solutions for high-temperature processes; alumina and zirconia for abrasives; and high-performance binders for dry mix mortars and floor screeds in the construction industry. It serves automotive and transportation, consumer and health care, energy and electronics, industry and equipment, iron, and steel industries. The company was incorporated in 1880 and is headquartered in Paris, France. Imerys S.A. is a subsidiary of Belgian Securities BV.

CAC 40 ended the session with IMERYS falling 6.67% to €33.84 on Monday while CAC 40 fell 0.18% to €7,478.16.

Earnings Per Share

As for profitability, IMERYS has a trailing twelve months EPS of €2.02.

PE Ratio

IMERYS has a trailing twelve months price to earnings ratio of 16.75. Meaning, the purchaser of the share is investing €16.75 for every euro of annual earnings.

Volatility

IMERYS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.39%, a negative 0.53%, and a positive 1.48%.

IMERYS’s highest amplitude of average volatility was 1.40% (last week), 2.04% (last month), and 1.48% (last quarter).

More news about IMERYS.

Stay up to date with our winners and losers daily report